<DOC>
	<DOCNO>NCT01024556</DOCNO>
	<brief_summary>The present study design prospective observational study direct evaluating frequency , magnitude , quality persistence ( primary endpoint ) anti-Tat immune response highly active antiretroviral therapy ( HAART ) -receiving HIV-1 infected individual , prospectively evaluate immunological , virological clinical outcome anti-Tat positive versus anti-Tat negative subject successful HAART ( secondary endpoint ) , order determine impact anti-Tat immunity HIV disease progression well potential use anti-Tat immune response assessment clinical therapeutic management HAART-treated infect patient . This survey provide important information design , plan conduction future therapeutic vaccine trial base HIV-1 Tat protein HAART-treated patient .</brief_summary>
	<brief_title>Observational Study Anti-Tat Immune Response HIV-1-infected HAART-treated Adult Subjects</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Diagnosis HIV1 infection To successful HAART treatment plasma viremia &lt; 50 copies/ml last 6 month prior initiation study , without history virologic rebound Known CD4+ T cell nadir Age â‰¥ 18 year old Signed informed consent Current therapy immunomodulators immunosuppressive drug , chemotherapy neoplastic disorder Concomitant treatment HBV HCV infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>HIV , HAART</keyword>
</DOC>